Compositions and methods relating to proliferative diseases
Anti-cancer compositions and methods are described herein. In particular, compositions including one or more of leelamine, a leelamine derivative, abietylamine, an abietylamine derivative, and an abietic acid derivative are described. Methods for treatment of pathological conditions particularly cancer, in a subject using one or more of leelamine, a leelamine derivative, abietylamine, an abietylamine derivative, and an abietic acid derivative are described herein.
1. An anti-cancer pharmaceutical composition, comprising: liposome encapsulated leelamine, wherein the liposomes comprise L-alpha-phosphatidylcholine and 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000 in an 80:20 mol % ratio and wherein the liposomes have a net neutral surface charge at physiological pH.
2. A method of treating a subject having cancer, comprising:
administering a therapeutically effective amount of the anti-cancer pharmaceutical composition of claim 1 to the subject.
3. The method of claim 2 , wherein the anti-cancer pharmaceutical composition is effective to preferentially inhibit the PI3K, MAPK and STAT pathways in a cancer cell compared to a non-cancer cell.
4. The method of claim 2 , wherein the subject is human.
5. The method of claim 2 , further comprising administration of an adjunct anti-cancer treatment.